Weiss Ratings Reiterates Sell (E+) Rating for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Key Points

• Weiss Ratings has reiterated its "sell (E+)" rating for Ironwood Pharmaceuticals, amidst varying opinions from other analysts who have recently upgraded the stock to "strong-buy" ratings.
• Ironwood Pharmaceuticals reported $0.14 EPS for the last quarter, exceeding expectations of a loss, and achieved a revenue of $85.24 million, surpassing estimates of $62.02 million.
• Despite the positive earnings, the stock has an average rating of "Hold" with a target price of $4.94, while its current trading price stands at $1.58.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report)'s stock had its "sell (e+)" rating reiterated by stock analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Several other research analysts also recently commented on the company. Wall Street Zen raised Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 9th. Zacks Research upgraded Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $4.94.

Ironwood Pharmaceuticals Stock Performance

Shares of NASDAQ IRWD opened at $1.58 on Wednesday. Ironwood Pharmaceuticals has a 52-week low of $0.53 and a 52-week high of $5.13. The business has a fifty day moving average of $1.21 and a two-hundred day moving average of $0.96. The stock has a market cap of $256.64 million, a PE ratio of -31.59 and a beta of 0.30.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its earnings results on Thursday, August 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.02) by $0.16. Ironwood Pharmaceuticals had a negative net margin of 2.25% and a negative return on equity of 2.46%. The business had revenue of $85.24 million during the quarter, compared to analysts' expectations of $62.02 million. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts predict that Ironwood Pharmaceuticals will post 0.1 earnings per share for the current year.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter worth $59,000. State of Wyoming increased its position in Ironwood Pharmaceuticals by 40.4% in the first quarter. State of Wyoming now owns 58,775 shares of the biotechnology company's stock worth $86,000 after purchasing an additional 16,917 shares during the period. Y Intercept Hong Kong Ltd increased its position in Ironwood Pharmaceuticals by 162.6% in the first quarter. Y Intercept Hong Kong Ltd now owns 39,782 shares of the biotechnology company's stock worth $58,000 after purchasing an additional 24,635 shares during the period. McAdam LLC bought a new stake in Ironwood Pharmaceuticals during the 1st quarter worth about $40,000. Finally, R Squared Ltd lifted its position in Ironwood Pharmaceuticals by 286.5% during the 2nd quarter. R Squared Ltd now owns 38,765 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 28,735 shares during the period.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.